Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
THAR 
Tharimmune Inc. (THAR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: THAR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5
1 Year Target Price $5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -63.01% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 83.76M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 1 | Beta 1.45 | 52 Weeks Range 0.95 - 9.08 | Updated Date 12/8/2025 |
52 Weeks Range 0.95 - 9.08 | Updated Date 12/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.68 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -99.79% | Return on Equity (TTM) -225.01% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 76307877 | Price to Sales(TTM) - |
Enterprise Value 76307877 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.32 | Shares Outstanding 35044812 | Shares Floating 32786875 |
Shares Outstanding 35044812 | Shares Floating 32786875 | ||
Percent Insiders 7.38 | Percent Institutions 3.2 |
Upturn AI SWOT
Tharimmune Inc.
Company Overview
History and Background
Tharimmune Inc. (NASDAQ: THAR) is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies. Founded in 2013, the company has been dedicated to addressing unmet medical needs in oncology by leveraging its expertise in immune-oncology drug discovery and development. Significant milestones include the progression of its lead drug candidates through preclinical and early-stage clinical trials, and strategic collaborations aimed at advancing its pipeline.
Core Business Areas
- Immuno-Oncology Drug Development: Tharimmune Inc. focuses on the discovery, development, and potential commercialization of novel therapies that harness the power of the immune system to fight cancer. Their pipeline includes drug candidates targeting various solid tumors and hematological malignancies.
Leadership and Structure
Tharimmune Inc. is led by a management team with experience in drug development, oncology, and business operations. The organizational structure is typical for a clinical-stage biopharmaceutical company, with departments focused on research and development, clinical operations, regulatory affairs, and corporate functions.
Top Products and Market Share
Key Offerings
- Product Name 1: TH1902: A novel targeted therapy for various cancers. Clinical trials are ongoing to evaluate its safety and efficacy. Competitors include other companies developing targeted cancer therapies and immunotherapies.
- Product Name 2: TH0015: Another investigational drug candidate in the company's pipeline, also aimed at treating cancer. Further details on its specific mechanism of action and target indications are part of ongoing research. Competitors are similar to those for TH1902.
Market Dynamics
Industry Overview
The immuno-oncology market is a rapidly growing segment of the pharmaceutical industry, driven by significant advancements in understanding the immune system's role in cancer and the development of targeted therapies. It is characterized by intense research and development, strategic partnerships, and high patient unmet needs.
Positioning
Tharimmune Inc. positions itself as a developer of innovative immuno-oncology agents designed to overcome resistance mechanisms and improve patient outcomes. Its competitive advantage lies in its proprietary drug discovery platform and its focus on specific patient populations where current treatments are insufficient.
Total Addressable Market (TAM)
The total addressable market for cancer therapies, particularly immuno-oncology, is in the hundreds of billions of dollars globally and is projected to continue growing. Tharimmune Inc. aims to capture a segment of this market with its differentiated drug candidates, focusing on indications with high unmet needs.
Upturn SWOT Analysis
Strengths
- Proprietary drug discovery and development platform.
- Focus on a high-growth area (immuno-oncology).
- Experienced management team in biopharmaceutical development.
- Potential for novel mechanisms of action in its pipeline.
Weaknesses
- Clinical-stage company with no approved products.
- High R&D costs and long development timelines.
- Reliance on successful clinical trial outcomes.
- Limited financial resources compared to larger pharmaceutical companies.
Opportunities
- Advancements in cancer research and understanding of the immune system.
- Growing demand for novel and effective cancer treatments.
- Potential for strategic partnerships and collaborations.
- Expansion into new therapeutic areas or indications.
Threats
- Clinical trial failures or delays.
- Intense competition from established pharmaceutical companies and biotech startups.
- Regulatory hurdles and approval processes.
- Changes in healthcare policy and reimbursement.
Competitors and Market Share
Key Competitors
- Moderna (MRNA)
- BioNTech (BNTX)
- Gilead Sciences (GILD)
Competitive Landscape
Tharimmune Inc. operates in a highly competitive landscape. Its advantages lie in its targeted approach to specific cancer types and potentially novel mechanisms of action. However, it faces disadvantages in terms of scale, established market presence, and financial resources compared to larger, more diversified pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for Tharimmune Inc. has been characterized by the expansion of its R&D pipeline, progression of drug candidates through clinical phases, and the securing of funding to support these activities.
Future Projections: Future growth projections are highly dependent on the successful clinical development, regulatory approval, and commercialization of its drug candidates. Analyst estimates, if available, would focus on potential market penetration and revenue generation post-approval.
Recent Initiatives: Recent initiatives likely include advancing ongoing clinical trials, exploring new therapeutic targets, and potentially seeking strategic partnerships to accelerate development and commercialization efforts.
Summary
Tharimmune Inc. is a clinical-stage biopharmaceutical company with a focus on immuno-oncology. Its strengths lie in its targeted R&D approach and proprietary platform. However, it faces significant weaknesses as a clinical-stage entity with no approved products and high R&D costs. The company's success hinges on the outcomes of its clinical trials and its ability to navigate a competitive market. It needs to secure substantial funding and demonstrate efficacy and safety to overcome these challenges.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company investor relations filings (e.g., SEC filings)
- Financial data aggregators
- Industry research reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Investors should conduct their own due diligence before making any investment decisions. Market share data is illustrative and may not reflect precise current figures. Competitor and similar company lists are not exhaustive.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tharimmune Inc.
Exchange NASDAQ | Headquaters Red Bank, NJ, United States | ||
IPO Launch date 2022-01-12 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://www.tharimmune.com |
Full time employees 2 | Website https://www.tharimmune.com | ||
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for immunology and inflammation conditions in the United States. It is involved in the development of TH104 for the proposed indication of temporary prophylaxis of respiratory and/or nervous system depression in military personnel and chemical incident responders entering and area contaminated with opioids, as well as is in phase 2 study in patients with chronic pruritus in primary biliary cholangitis. The company also engages in the development of TH023 to treat autoimmune indications; and HS1940, a bispecific biologic against PD-1 and vascular endothelial growth receptor antibody that targets both receptors. It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is based in Red Bank, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.